WO1997002835A1 - Intranasal vaccination against gastrointestinal disease - Google Patents

Intranasal vaccination against gastrointestinal disease Download PDF

Info

Publication number
WO1997002835A1
WO1997002835A1 PCT/US1996/010987 US9610987W WO9702835A1 WO 1997002835 A1 WO1997002835 A1 WO 1997002835A1 US 9610987 W US9610987 W US 9610987W WO 9702835 A1 WO9702835 A1 WO 9702835A1
Authority
WO
WIPO (PCT)
Prior art keywords
toxin
difficile
composition
toxoid
immunization
Prior art date
Application number
PCT/US1996/010987
Other languages
English (en)
French (fr)
Inventor
William D. Thomas, Jr.
Thomas P. Monath
Francisco Torres-Lopez
Zhenxi Zhang
Wende Lei
David M. Lyerly
James S. Moncrief
Original Assignee
Oravax, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oravax, Inc. filed Critical Oravax, Inc.
Priority to AU64799/96A priority Critical patent/AU722653B2/en
Priority to EP96924312A priority patent/EP0877623A1/en
Priority to NZ312876A priority patent/NZ312876A/en
Priority to JP9505849A priority patent/JPH11510793A/ja
Publication of WO1997002835A1 publication Critical patent/WO1997002835A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to intranasal vaccination methods for preventing and/or treating gastrointestinal disease.
  • Clostridium difficile is a gram-positive, spore- forming, toxigenic bacterium that causes antibiotic- associated diarrhea which can progress into severe and sometimes fatal colitis.
  • C. difficile Upon disruption of the normal intestinal flora by, e.g., antibiotic or anti-neoplastic therapy, C. difficile may become established in the colon where it produces two high molecular weight toxins, Toxin A and Toxin B. Both of these polypeptides are cytotoxins, but Toxin B is greater than 1000-fold more potent than Toxin A.
  • Toxin A is also an enterotoxin, as it causes accumulation of fluid in ligated animal intestinal loops.
  • Vaccination of hamsters with C. difficile toxins A or B (or toxoids) using either of these methods gives rise to protection of these animals from subsequent C. difficile challenge.
  • the invention features a method of inducing a distal mucosal immune response (i.e., a mucosal immune response outside of the upper respiratory tract, e.g., in the gastrointestinal and/or genitourinary tracts) to a gastrointestinal or genitourinary tract pathogen in a mammal.
  • a distal mucosal immune response i.e., a mucosal immune response outside of the upper respiratory tract, e.g., in the gastrointestinal and/or genitourinary tracts
  • a non-replicatable polypeptide antigen which is dissolved in a pharmaceutically acceptable diluent, and which is capable of inducing the distal immune response to the pathogen, is administered intranasally to the mammal.
  • the invention also features a method of inducing a distal mucosal immune response to a pathogen in a mammal involving: (1) administering an antigen capable of inducing the distal immune response to a mucosal surface of the mammal, and (2) parenterally administering the antigen to the mammal.
  • Any order of combined mucosal and parenteral administration is included in the invention.
  • mucosal e.g., intranasal, oral, ocular, gastric, rectal, vaginal, gastrointestinal, or urinary tract
  • parenteral e.g., intravenous, subcutaneous, intraperitoneal, or intramuscular
  • parenteral administration may precede mucosal administration.
  • three weekly doses may be administered mucosally (e.g., intranasally) and, on the fourth week, combined mucosal (e.g., intranasal) and parenteral (e.g., intraperitoneal) administration may carried out.
  • mucosally e.g., intranasally
  • parenteral e.g., intraperitoneal
  • Pathogens to which mucosal immune responses may be induced in the methods of the invention, and from which the antigens (e.g., non-replicatable polypeptide antigens) may be derived include, but are not limited to gastrointestinal pathogens such as Helicobacter ⁇ (e.g., H. pylori , H. feli ⁇ , and H. heilmanii) , Campylobacters (e.g., C. jejuni) , pathogens which cause diarrhea and colitis (e.g., Clostridia (e.g., C. difficile, C. novyi , and C. sordellii) , enterotoxigenic E.
  • Helicobacter ⁇ e.g., H. pylori , H. feli ⁇ , and H. heilmanii
  • Campylobacters e.g., C. jejuni
  • pathogens which cause diarrhea and colitis e.g., Clostridia
  • antigens e.g., non- replicatable polypeptide antigens
  • toxins from Clostridia e .g. , C . difficile , C. novyi , and C.
  • sordellii such as C. difficile Toxin A and/or B Toxoid, C. novyi ⁇ -toxin (Bette et al . , Toxicon 29(7) :877-887, 1991), C. sordellii lethal toxin (Bette et al . , supra) , and immunogenic fragments and derivatives thereof, may be used.
  • the antigens used in the methods of the invention may be obtained by standard methods known in the art, e.g., purification from a culture of the pathogen from which it is derived, recombinant DNA methods, and chemical synthetic methods.
  • the invention may employ Clostridium (e . g. ,
  • a toxoid is a toxin (or mixture of toxins, e .g. , C. difficile Toxin A and Toxin B) that has been treated so as to decrease the toxic properties of the toxin(s) , but to retain antigenicity.
  • Toxoids included in the invention are made using standard methods including, but not limited to, chemical (e.g., formaldehyde or glutaraldehyde) treatment, protease cleavage, and recombinant methods (e.g., by making fragments or mutations (e.g., point mutations) of the toxin(s)).
  • the method of the invention may be carried out in order to prevent or decrease the chances of a future infection by a pathogen (i.e., to induce a protective immune response) and/or to treat an ongoing infection (i.e., to induce a therapeutic immune response).
  • a pathogen i.e., to induce a protective immune response
  • an ongoing infection i.e., to induce a therapeutic immune response
  • the method of the invention may be used to treat a mammal that is at risk of developing, but does not have, diarrhea caused by the pathogen (e.g., C. difficile) , or a mammal that has diarrhea caused by the pathogen.
  • Mammals which may be treated according to the method of the invention include, e .g. , humans, cows, horses, pigs, dogs, cats, sheep, and goats.
  • An advantage of the methods of the invention is that, for at least some antigens (e.g., C. difficile toxins and toxoids) , mucosal adjuvants are not required for induction of an immune response (e.g., a protective immune response) .
  • an immune response e.g., a protective immune response
  • Pig. 1 is a graph showing the levels of protection against C. difficile disease in hamsters immunized with C. difficile antigens by the indicated routes. The levels of protection from systemic (death) and intestinal (diarrhea) disease after clindamycin challenge are shown. (See Table 1 for a description of the immunization routes.)
  • Pig. 2 is a graph showing the mean (+SE) antibody titers to C. difficile Toxin A, Toxin B, and whole cell antigens in sera from hamsters after 3 doses of vaccine administered by the routes indicated, as determined by ELISA. (See Table 1 for a description of the routes of immunization.) Sera from hamsters after 3 doses of vaccine were assayed for specific IgG; the titer was defined as the maximum dilution with an absorbance of >0.3. Each bar represents the mean (+SE) of five animals.
  • Pig. 3 is a graph showing the biological activity of sera from hamsters administered 3 doses of vaccine by the indicated routes. Sera were tested for inhibition of cytotoxin A or cytotoxin B activity in IMR-90 cells, and for agglutination of C. difficile cells; titers were defined as the maximal dilution with biological activity. Each bar represents the mean (+SE) of five animals. (See Table 1 for a description of the routes of immunization.)
  • Pig. 4 is a graph showing the long term antibody response in i.n.i.p. and s.c. immunized hamsters. Comparisons of the responses before clindamycin challenge (i.n.i.p.-I and s.c.-I) and 140 days after clindamycin challenge (i.n.i.p.-II and s.c.-II) are shown. Sera were tested by ELISA against Toxin A, Toxin B, and whole cell antigens, and the titers were expressed as the maximal dilution with absorbance >0.3; each bar represents the mean (+SE) of five animals.
  • Fig. 5 is a graph showing the long term antibody response in i.n.i.p. and s.c. immunized hamsters. Comparisons of the responses before clindamycin challenge (i.n.i.p.-I and s.c.-I) and 140 days after clindamycin challenge (i.n.i.p.-II and s.c.-II) are shown. Sera was tested for inhibition of cytotoxins in IMR-90 cells and for agglutination of C. difficile cells; the titer was the maximal dilution of serum with biological activity. Each bar represents the mean (+SE) of five animals.
  • Figs. 6A-6B are graphs showing the anti-Toxin A (Fig.
  • Figs. 7A-7C are graphs showing the serum anti- Toxin B cytotoxicity after intranasal immunization of mice with toxoid (Fig. 7A) , the serum anti-Toxin A cytotoxicity after intranasal immunization with toxoid (Fig. 7B) , and the salivary and vaginal secretion anti- Toxin A cytotoxicity after intranasal immunization with toxoid (Fig. 7C) .
  • Fig. 8 is a graph showing the level of passive protection of ligated small intestinal loops of rats from Toxin A using sera from mice immunized intranasally with toxoid.
  • Pig. 9 is a graph showing the percent survival of mice intranasally immunized with toxoid after lethal challenge with Toxin A or Toxin B.
  • Pig. 10 is a graph showing the level of Toxin A enterotoxicity in ligated intestinal loops of mice after intranasal immunization of toxoid.
  • Figs. 11A-11B are graphs showing the Toxin A- specific systemic (Fig. IIA) and mucosal (Fig. IIB) IgA responses after immunization with GST-ARU by the indicated routes. (See Table 5 for a description of the routes of immunization.)
  • Figs. 12A-12B are graphs showing the levels of Toxin A cytotoxicity inhibition of sera taken 40 days after immunization with GST-ARU. (See Table 5 for a description of the routes of immunization.)
  • Figs. 13A-13B are graphs showing the levels of passive inhibition of Toxin A enterotoxicity in rat intestinal loops with immune sera from GST-ARU immunized mice. (See Table 5 for a description of the routes of immunization.)
  • Fig. 14 is a graph showing the percent survival from lethal Toxin A challenge after immunization with recombinant Toxin A repeats (ARU) . (See Table 5 for a description of the routes of immunization.)
  • Fig. 15 is a graph showing the levels of protection from enterotoxicity of Toxin A in ligated mouse intestinal loops after immunization with GST-ARU. (See Table 5 for a description of the routes of immunization.) Intranasal and Combined Mucosal-Systemic Vaccination Methods for Inducing Mucosal Immune Responses at Distal Sites
  • the methods of the invention may be used to induce protective and/or therapeutic immune responses to gastrointestinal pathogens including, but not limited to, Helicobacters (e . g. , H. pylori , H. felis , and H. heilmanii) Campylobacters (e . g. , C. jejuni) , and pathogens which cause diarrhea and colitis, e . g. , Clostridia , enterotoxigenic E.
  • Helicobacters e . g. , H. pylori , H. felis , and H. heilmanii
  • Campylobacters e . g. , C. jejuni
  • pathogens which cause diarrhea and colitis e . g. , Clostridia , enterotoxigenic E.
  • genitourinary tract pathogens e.g., human immunodeficiency virus, herpes simplex viruses, papilloma viruses, Treponema pallidum, Chlamydia , and Neisseria gonorrhoeae
  • vaccine antigens e.g., polypeptide antigens
  • the methods of the invention are described, as follows, referring to antigens from C. difficile (e .g. , toxins or toxoids) as specific examples of vaccine antigens which may be used in the methods of the invention.
  • C. difficile toxin polypeptides which may be used in the methods and compositions of the invention can be prepared using any of several standard methods.
  • the toxins e.g., Toxin A and/or Toxin B
  • C. difficile culture filtrates see, e.g., Kim et al . , Infection and Immunity 55:2984-2992, 1987; and see Example I, below.
  • C. difficile toxin polypeptides can also be produced using standard recombinant DNA methods (see, e .g. , Ausubel et al . , Eds., Current Protocols in
  • a suitable host cell is transformed with an appropriate expression vector containing all or part of a toxin-encoding nucleic acid fragment (see Dove et al . , Infection and Immunity 58:480-488, 1990, and Barroso et al . , Nucleic Acids Research 18:4004, 1990, for the nucleotide and deduced amino acid sequences of C. Difficile Toxin A, and the nucleotide sequence of Toxin B, respectively) . Any of a variety of expression systems can be used to produce the recombinant toxins.
  • the toxin polypeptides can be produced in a prokaryotic host (e.g., E. coli) or in a eukaryotic host (e.g., yeast cells (e.g., Saccharomyces cerevisiae) , mammalian cells (e.g., COS1, NIH3T3, or JEG3 cells), or arthropod cells (e.g., Spodoptera frugiperda (SF9) cells) ) .
  • yeast cells e.g., Saccharomyces cerevisiae
  • mammalian cells e.g., COS1, NIH3T3, or JEG3 cells
  • arthropod cells e.g., Spodoptera frugiperda (SF9) cells
  • transfection/transformation method used will depend on the host system selected, as is described by, e.g., Ausubel et al . , supra.
  • Expression vectors e.g., plasmid or viral vectors
  • C. difficile toxin polypeptides can also be produced by chemical synthesis, e.g., by the method described in Solid Pha ⁇ e Peptide Synthesis, 1984, 2nd ed. , Stewart and Young, Eds., Pierce Chemical Co., Rockford, IL, and by standard in vitro translation methods.
  • Toxoids of C. difficile toxins can also be used in the methods of the invention.
  • a toxoid is a toxin that has been treated so that the toxicity of the toxin is eliminated or reduced, but the antigenicity is maintained.
  • Toxoids may be prepared using standard methods, for example, by chemical (e.g., glutaraldehyde or formaldehyde) treatment (see, e.g., Libby et al . , Infection and Immunity 36:822-829, 1982). Toxoids may also be prepared by making mutations in the genes encoding the toxins and expressing the mutated genes in an expression system, as is described above.
  • Regions in Toxin A and/or Toxin B that can be mutated include, e.g., the conserved cysteine residues, the nucleotide binding region, the internal hydrophobic region, and/or the carboxyl-terminal repeat regions.
  • Specific examples of such mutations in C. difficile toxins which can be used in the invention are described by, e.g., Barroso et al . , Microbial Pathogenesis 16:297-303, 1994.
  • reagents which specifically modify SH-containing amino acids, lysine, tyrosine, tryptophan, or histidine residues are known in the art (see, e.g., Cohen et al . , Ann. Rev. Biochem. 37:683-695, 1968).
  • azido-linked substrate analogs such as UDP-glucose, which can be covalently linked to toxin active sites by ultraviolet irradiation, can be used to produce toxoids.
  • C. difficile toxins In addition to native, full length, C. difficile toxins, polypeptide fragments of toxins, or toxins (or polypeptide fragments of toxins) containing mutations (which may or may not be toxoids) can be used in the invention, provided that antigenicity is retained.
  • fragments of C. difficile toxins see, e . g. , Price et al . , Current Microbiology 16:55-60, 1987; Lyerly et al . , Current Microbiology 21:29-32, 1990; and Frey et al . , Infection and Immunity 60:2488-2492, 1992. Genes encoding fragments of C.
  • fragments, derivatives, and toxoids included in the invention can be screened for antigenicity using standard methods in the art, e.g., by measuring induction of a mucosal immune response (see below) , induction of protective immunity (see below) , or induction of a therapeutic immune response.
  • adjuvants may be administered with the vaccines in the methods of the invention. Any of a number of adjuvants that are known to one skilled in the art may be used.
  • a cholera toxin (CT)
  • the heat-labile enterotoxin of Escherichia coli (LT) or fragments or derivatives thereof having adjuvant activity
  • An adjuvant such as RIBI (ImmunoChem, Hamilton, MT) or aluminum hydroxide can be used for parenteral administration.
  • Fusion proteins containing a C. difficile toxin (or a fragment or derivative thereof) fused to, e.g., an adjuvant (e.g., CT, LT, or a fragment or derivative thereof having adjuvant activity) are also included in the invention, and can be prepared using standard methods (see, e .g.
  • the vaccines of the invention can be covalently coupled or cross-linked to adjuvants.
  • Methods for covalently coupling and chemically cross-linking adjuvants to antigens are described by, e.g., Cryz et al . , Vaccine 13:67-71, 1994; Liang et al . , J. Immunology 141:1495- 1501, 1988; and Czerkinsky et al . , Infection and Immunity 57:1072-1077, 1989.
  • vaccine compositions are administered intranasally according to the methods of the invention.
  • Combined modes of administration may also be used, e.g., the first dose of the vaccine can be administered to a mucosal (e.g., intranasal or oral) surface, and booster immunizations can be administered parenterally (e.g., intraperitoneally or subcutaneously) ; this combination gives unexpectedly good results.
  • a parenteral booster immunization may be given one week after the first, mucosal administration.
  • the amount of vaccine administered depends on the particular vaccine antigen, whether an adjuvant is co- administered with the vaccine antigen, the mode and frequency of administration, and the desired effect (e.g., protection and/or treatment), as can be determined by one skilled in the art.
  • the vaccine antigens of the invention are administered in amounts ranging between, e.g., 1 ⁇ g and 100 mg. If adjuvants are administered with the vaccines, amounts ranging between, e.g., 1 ng and 1 mg can be used. Administration is repeated as necessary, as can be determined by one skilled in the art. For example, a priming dose can be followed by 3 booster doses at weekly intervals.
  • Vaccines may be administered in any pharmaceutically acceptable carrier or diluent (e.g., water, a saline solution (e.g., phosphate-buffered saline), or a bicarbonate solution (e.g., 0.2 M NaHC0 3 )) .
  • a pharmaceutically acceptable carrier or diluent e.g., water, a saline solution (e.g., phosphate-buffered saline), or a bicarbonate solution (e.g., 0.2 M NaHC0 3 )
  • the carriers and diluents used in the invention are selected on the basis of the mode and route of administration, and standard pharmaceutical practice. Suitable pharmaceutical carriers and diluents, as well as pharmaceutical necessities for their use in pharmaceutical formulations, are described in Remington 's Pharmaceutical Sciences , a standard reference text in this field, and in the USP/NF.
  • the hamster model may also be used to monitor the immune response induced by the vaccination methods of the invention.
  • serum and mucosal samples from immunized hamsters can be used to measure inhibition of in vitro cytotoxicity.
  • ligated intestinal loops of immunized hamsters can be used to evaluate the inhibition of the enterotoxic activity of Toxin A induced by vaccination.
  • colonization of hamsters with C. difficile can be monitored by fecal culture, or the presence of Toxin A and/or Toxin B in hamster feces can be determined by ELISA and/or cytotoxicity analysis.
  • mice mucosal immune response a subset of antibodies which recognize mouse IgA are commercially available, and thus facilitate evaluation of the mouse mucosal immune response.
  • such reagents are not available for evaluating the hamster mucosal immune response.
  • An additional advantage of the mouse model is that methods for sampling mouse mucosal surfaces have been developed which allow mucosal responses to various immunization regimens to be mapped.
  • mouse serum samples can be used to investigate properties of the antibodies which are likely to be associated with effective vaccines.
  • serum from immunized mice can be analyzed for its ability (1) to inhibit in vitro cytotoxicity of Toxin A and/or Toxin B, or (2) to inhibit the enterotoxicity of Toxin A using ligated intestinal loops of mice or rats challenged with Toxin A.
  • Immunized mice may also be challenged orally, or in their ligated intestinal loops, to determine protection from death or fluid accumulation due to Toxin A enterotoxicity.
  • immunized mice may be challenged with toxins systemically with doses known to be lethal.
  • Example I Immunization of Hamsters with Vaccine Compositions Containing C. difficile Toxins
  • C. difficile culture filtrate was prepared and inactivated as described by Libby, et al . (Infection and Immunity 36:822-829, 1982). Briefly, C. difficile VPl strain 10463 (ATCC accession number 43255) was grown for 3 days in dialysis flasks, centrifuged, and filter sterilized. One ml of formaldehyde was added to 100 ml of the culture filtrate, and the mixture was incubated at 37°C for 1 hour. The culture filtrate had a concentration of approximately 50 ⁇ .g/ml of Toxin A, as determined by ELISA (Lyerly, et al .
  • C. difficile VPl strain 10463 (ATCC accession number 43255) was grown in proteose peptone-yeast extract media (PPY; Holbrook, et al . J. Appl. Bacteriol. 42:259- 273, 1977) at 37°C for 36 hours under anaerobic conditions to minimize spore formation.
  • the cultures were centrifuged and the pelleted cells were washed 3 times with PBS. After the final wash, the pelleted cells were resuspended in PBS containing 1% (vol:vol) formaldehyde and incubated at 4°C for 24 hours. Excess formaldehyde was removed by 3 washes with PBS, and the formalinized C. difficile cell suspension was stored at 4°C.
  • CFU C. difficile colony-forming units
  • ⁇ g of each toxoid were mixed with 10 ⁇ g of cholera toxin, adjusted to a volume of 1 ml with PBS, and administered by gavage.
  • i.p. intraperitoneal
  • s.c. subcutaneous
  • 5 ⁇ g of each toxoid were mixed with 0.3 ml of RIBI adjuvant (RIBI, ImmunoChem, Hamilton, MT) .
  • RIBI adjuvant RIBI, ImmunoChem, Hamilton, MT
  • rectal (r.) immunization 50 ⁇ g of each toxoid, in 100 ⁇ l of toxoid, were mixed with a 1 ⁇ l solution containing 10 ⁇ g of cholera toxin.
  • a control intranasal group (c.i.n.) received 5 ⁇ g of cholera toxin intranasally.
  • a control subcutaneous group (c.s.c.) received 0.3 ml of RIBI adjuvant subcutaneously. Groups of 5 animals were used for all immunization regimens. All groups received a total of 4 doses of the vaccine (or adjuvant control) on days 0, 7, 14, and 28 of the experiment.
  • samples (200- 400 ⁇ l) of blood were obtained on days 0, 2, 4, 7, and 36 from the retro-orbital sinus of the hamsters under isofluorane anesthesia.
  • the blood was left to clot overnight at 4°C, and the serum was obtained by centrifugation. Only serum antibodies were evaluated; secretory IgA was not measured because of a lack of a suitable anti-hamster IgA reagent.
  • C. difficile challenge a sample of feces was obtained every other day from the surviving animals and mixed with 2 volumes of PPY media for evaluation of the degree of colonization and presence of toxins (see below) .
  • Severely ill hamsters were euthanized. Samples of cecum from the euthanized hamsters, and from the survivors from every immunization regimen, taken 8 days after clindamycin challenge, were fixed in 10% neutral buffered formalin. Formalin-fixed tissues were embedded in paraffin, sectioned at 5 ⁇ M, stained with hematoxylin and eosin, and examined by light microscopy.
  • Histologic grading criteria were: 0, minimal infiltration of lymphocytes, plasma cells, and eosinophils; 1+, mild infiltration of lymphocytes, plasma cells, neutrophils, and eosinophils, plus mild congestion of the mucosa, with or without hyperplasia of gut associated lymphoid tissue; 2+, moderate infiltration of mixed inflammatory cells, moderate congestion and edema of the lamina intestinal, with or without goblet cell hyperplasia, individual surface cell necrosis or vacuolization, and crypt dilatation; and 3+, severe inflammation, congestion, edema, and hemorrhage in the mucosa, surface cell necrosis, or degeneration with erosions or ulcers. Evaluation of infections
  • Feces obtained after clindamycin challenge were studied for the presence of C. difficile .
  • Ten-fold dilutions in PPY media were inoculated onto selective media containing cycloserine (125 ⁇ g/ml) and cefoxitin (8 ⁇ g/ml) , and colonies were counted after 48 hours of incubation under anaerobic conditions.
  • the presence of Toxin A in feces was determined using a Toxin A kit (TechLab, Blacksburg, VA) , as described by the manufacturer. After 15 minutes with substrate, the O.D. was read at 450 nm, and the concentration of toxin was estimated from a standard curve of Toxin A prepared in each plate.
  • Toxin B fecal suspensions were centrifuged and filter-sterilized, and ten-fold dilutions of the samples were tested for cytopathic effects on IMR- 90 fibroblast cell cultures, as is described below.
  • ELISA for Antibodies to Toxin A and Toxin B Microtiter plates were coated with 100 ng/well of purified Toxin A or Toxin B in carbonate-bicarbonate buffer, pH 9.3, and incubated overnight at 4°C.
  • NFDM non-fat dry milk
  • PBS phosphate buffered saline solution
  • Serum samples were added at two-fold dilutions ranging from 1:500 to 1:64,000, and the plates were incubated for 1 hour at 37°C.
  • a positive control was included in each plate; wells were coated with Toxin A or Toxin B in two-fold dilutions ranging from 100 to 0.8 ng/ml, and reacted with specific goat anti-toxin (TechLab) , followed by an anti-goat IgG alkaline phosphatase conjugate. Negative controls were wells coated with purified toxin and reacted with an anti-hamster IgG alkaline phosphatase conjugate. The O.D. was read at 405 nm, and the titer was defined as the reciprocal of the highest dilution of sample giving an O.D. > 0.3.
  • IMR-90 fibroblast cells were grown to confluence in 96-well plates in D-MEM media (Gibco, Grand Island, NY) containing 10% fetal calf serum.
  • the minimal dose of Toxin A or Toxin B needed to cause 100% rounding of the cells was defined as 1 cytotoxic unit (CTU 100 ) .
  • CTU 100 cytotoxic unit
  • Toxin A 6.3 ng/ml
  • Toxin B 125 pg/ml
  • Two-fold dilutions of the hamster serum samples ranging from 1:100 to 12,800, were mixed with 4CTU 100 of either toxin, incubated for 1 hour at 37°C, and the mixture was then added to the cells.
  • Goat anti-Toxin A and goat anti-Toxin B served as positive controls. Cells were observed after 24 hours, and the proportion of round cells was determined. The titers of the samples were defined as the reciprocal of the highest dilution of sera inhibiting >50% cell rounding. Agglutination
  • C. difficile VPl strain 10463 ATCC accession number 43255
  • the strains isolated from hamsters after clindamycin challenge were grown in 5 ml of PPY media at 37°C under anaerobic conditions for 36 hours.
  • the cultures were centrifuged and the pellets were washed three times with PBS.
  • the pellets were resuspended in 250 ⁇ l of 3% SDS in PBS, and the lysates were fractionated by electrophoresis in a 12% preparative SDS- polyacrylamide gel (Bio-Rad, Hercules, CA) at 200 volts for 1 hour. Proteins were transferred from the gel to nitrocellulose at 150 volts for 1.2 hours in a Bethesda Research Laboratories Mini-V 8-10 chamber (Life Technologies, Grand Island, NY) .
  • Vaccinated hamsters that succumbed to challenge also died within the first 48 hours, and most had grade 3+ diarrhea and grade 3+ typhlitis on histopathologic examination. Animals that survived challenge either had no diarrhea or had diarrhea ranging in severity from 1+ to 3+. The severity of diarrhea correlated with the severity of typhlitis on pathologic examination. Animals with 3+ diarrhea had subacute, diffuse mucopurulent typhlitis grades 2-2.5+. Neutrophils, lymphocytes, and plasma cells infiltrated the lamina intestinal, and multifocal crypt abscesses also were noted. Those animals with 2+ diarrhea had subacute to chronic, moderate typhlitis grade 1.5-2+.
  • Serum antibodies against C. difficile antigens were measured in hamsters from all experimental groups. Immune responses to Toxin A after the priming immunization were studied by ELISA in some of the groups. No specific IgG was detected in animals vaccinated by the i.n.i.p., r., and w.c.r. routes on days 2, 4, and 7 after the initial vaccine dose. In the parenterally immunized animals (i.p. and s.c), no response was evident after days 2 and 4, but at day 7, a slight rise in antibody titer was observed. In contrast, the antibody responses measured after the last vaccine dose (day 36) demonstrated sero-conversion in all groups. The absence of early (anamnestic) antibody responses to the first vaccine dose shows that the animals were immunologically naive and had not previously been primed with Toxin A.
  • Antibody levels against whole cell antigens showed a pattern similar to that observed with toxins.
  • Antibodies to whole cell antigens were further characterized by Western blot analysis with whole cell lysates from the C. difficile strain isolated from the hamsters after clindamycin challenge. Animals in all immunization regimens developed antibodies to a 70 kD protein and to proteins with sizes of >200 kD (which are likely to be the toxins) ; animals immunized by the i.n.i.p. route had the strongest immune responses. A variety of other proteins were recognized by sera from animals immunized by the i.n.i.p., i.p., and s.c.
  • Serum antibodies with biological functions showed a different pattern from that obtained by ELISA (Fig. 3) .
  • Antibodies inhibiting cytotoxicity by Toxin A were elicited in all animals.
  • Hamsters immunized by the i.n.i.p. and i.p. routes developed the highest anti-toxin A activity (mean +SE 22,000 ⁇ 4,900 and 18,000 ⁇ 2,000, respectively), whereas mucosally immunized animals (i.n., i.g., r. and w.c.r.) had lower activities (580 ⁇ 280, 280 ⁇ 146, 1720 ⁇ 560, and 2760 ⁇ 290, respectively).
  • High anti-Toxin B responses were obtained in all groups, except in rectally immunized animals.
  • Agglutinating antibodies were elicited only in animals that received toxoid vaccine parenterally (i.p. and s.c), or by a combined mucosal-parenteral route (i.n.i.p.) .
  • Correlation of the Immune Response and Protection The i.n.i.p. immunized animals were fully protected against death and diarrhea and had the highest serum immune responses when both ELISA and biological activity were considered (Figs. 2 and 3) . Complete protection against death was provided by all immunization schemes that included parenteral injection of the vaccine or intranasal immunization alone. In contrast, rectally immunized animals had the lowest protection ratios and serum antibody responses, particularly neutralizing antibody against Toxin B (Fig.
  • Immunoassay Mean ⁇ SE Mean 1 SE p value a toxin A ELISA 9400 1970 13331160 . 0003 toxin B ELISA 17 , 80013430 8701230 . 0001 whole cell ELISA 900011660 18201310 . 0001 anti-cytotoxin A 15840+3690 32201610 . 0016 anti-cytotoxin B 1154014770 6701440 . 005
  • Example II Immunization of Mice with Vaccine Compositions Containing: C. difficile Toxins
  • the following methods were used to analyze the efficacy of the immunization methods of the invention in the mouse model system. ELISA
  • toxin-specific immune responses were detected by coating 96-well plates with Toxin A or Toxin B, blocking the wells with skim milk in PBS-tween, addition of samples from the mice, and detection with a commercial anti-mouse alkaline phosphatase (AP) conjugated reagent.
  • the plates were developed with Sigma 104 alkaline phosphatase (AP) substrate (Sigma Chemical Company, St. Louis, MO) . Data from these assays are represented as the absorbance at 405 nm (see below) .
  • IMR-90 fibroblast cells
  • IMR-90 cells are sensitive to 10-100 pg of Toxin A and 0.1-1.0 pg of Toxin B.
  • the dosage of toxins used in cytotoxicity inhibition experiments corresponds to 8x the amount required to cause rounding of 50% of a confluent monolayer of IMR-90 cells.
  • Serum or secretions were diluted appropriately and mixed with either Toxin A or Toxin B for 1 hour at 37°C. The toxins were then added to confluent wells of a 96-well cell culture plate and incubated overnight. Plates were read using a phase contrast microscope. Data are presented as the highest dilution that protects 50% of the monolayer from rounding.
  • Toxoid and recombinant Toxin A were prepared as is described above. Enterotoxicity
  • Toxin A enterotoxicity was assessed using ligated intestinal loops challenged with Toxin A. Antibodies inhibiting enterotoxicity were measured by challenging loops with Toxin A pre-incubated with sera or secretions containing antibodies. Rats were fasted prior to use, anesthetized, and sections of intestine were tied off. Each loop contains intact blood vessels and is free of feces. Toxin A (1-10 ⁇ g) was administered to the lumen of each loop, with and without pre-treatment with immune sera. After 4 hours, the loops were removed and the contents weighed. Mouse and hamster loops can be directly challenged in a similar fashion to determine the efficacy of immunization against enterotoxicity. In the mouse loop assay, the volume in PBS treated loops is compared to Toxin A treated loops. The data is presented as the mg of contents per cm of ligated loop. Systemic Challenge
  • mice were challenged with lOx the LD 50 of each toxin administered intraperitoneally.
  • the data shown in the figure is the % animals surviving the challenge.
  • Hamsters were challenged with 2 mg clindamycin and 1 x IO 7 vegetative C. difficile organisms.
  • mice Groups of 5 female Swiss Webster mice (Taconic Farms, Germantown, NY) were immunized weekly by the intranasal route with toxoid (15 ⁇ g of each toxin) , with or without 5 ⁇ g CT as a mucosal adjuvant.
  • the immunization scheme is summarized in Table 4. Serum, saliva, feces, and vaginal secretions were obtained after immunization. Specific IgA and IgG antibodies can be detected in serum, and specific IgA antibodies against both Toxin A and Toxin B can be detected in saliva, feces and on mucosal surfaces against both Toxin A and Toxin B after immunization (Figs. 6A and 6B) . This response was apparent regardless of the administration of CT along with the toxoid. Serum from immunized animals also inhibited the cytotoxicity of both Toxin A and Toxin B
  • FIGs. 7A-7C Immune sera was used to passively protect rat loops from the enterotoxic effects of Toxin A (Fig. 8) . Animals were challenged with 10 LD 50 of Toxin A followed by 10 LD 50 of Toxin B one week later. All immunized animals survived this challenge, while controls did not (Fig. 9) . Finally, ligated intestinal loops from immunized animals were challenged with Toxin A, directly demonstrating the induction of antibodies, which were probably mucosal IgA antibodies, capable of inhibiting fluid accumulation and, presumably, diarrhea (Fig. 10) . These data demonstrate the C. difficile vaccine elicits a strong protective mucosal immune response when administered to a mucosal surface, and that does not require a mucosal adjuvant.
  • Example III Immunization of Mice with Vaccine Compositions Containing GST-ARU fusion proteins
  • the COOH-terminal region of C. difficile Toxin A contains a series of repeating amino acid units which are thought to be involved in binding of the toxin to carbohydrate residues on target cells (see, e .g. , Lyerly et al.. Current Microbiology 21:29-32, 1990; Frey et al. , Infection and Immunity 60:2488-2492, 1992; and references cited therein) .
  • a fusion protein consisting of the carboxyl-terminal region of C. difficile Toxin A fused to glutathione S-transferase (GST) was constructed, as follows.
  • mice were immunized with Toxin A fusion protein (GST-ARU) by the intragastric (IG; 100 ⁇ g) , intranasal (IN; 50 ⁇ g) , or intraperitoneal (IP; 25 ⁇ g) routes, with or without CT (5 ⁇ g) as a mucosal adjuvant, in four weekly doses (Table 5) .
  • IG intragastric
  • IgA intranasal
  • IP intraperitoneal
  • GST-ARU 100 CT IG 5 GST-ARU 100 none IG 5 GST-ARU 50 CT IN 5 GST-ARU 50 none IN 5 GST-ARU 25 RIBI IP 5 GST-ARU 25 none IP 5 PBS 0 CT IN 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US1996/010987 1995-07-07 1996-06-26 Intranasal vaccination against gastrointestinal disease WO1997002835A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU64799/96A AU722653B2 (en) 1995-07-07 1996-06-26 Intranasal vaccination against gastrointestinal disease
EP96924312A EP0877623A1 (en) 1995-07-07 1996-06-26 Intranasal vaccination against gastrointestinal disease
NZ312876A NZ312876A (en) 1995-07-07 1996-06-26 Intranasal, muscosal and systemic vaccination against C. difficile inducing a mucosal immune response in the gastrointestinal and/or genitourinary tracts
JP9505849A JPH11510793A (ja) 1995-07-07 1996-06-26 胃腸病に対する鼻腔内ワクチン接種

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49922995A 1995-07-07 1995-07-07
US08/499,229 1995-07-07

Publications (1)

Publication Number Publication Date
WO1997002835A1 true WO1997002835A1 (en) 1997-01-30

Family

ID=23984386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/010987 WO1997002835A1 (en) 1995-07-07 1996-06-26 Intranasal vaccination against gastrointestinal disease

Country Status (8)

Country Link
EP (1) EP0877623A1 (enrdf_load_stackoverflow)
JP (1) JPH11510793A (enrdf_load_stackoverflow)
CN (1) CN1195993A (enrdf_load_stackoverflow)
AU (1) AU722653B2 (enrdf_load_stackoverflow)
CA (1) CA2226392A1 (enrdf_load_stackoverflow)
NZ (1) NZ312876A (enrdf_load_stackoverflow)
WO (1) WO1997002835A1 (enrdf_load_stackoverflow)
ZA (1) ZA965737B (enrdf_load_stackoverflow)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
WO2001032713A1 (en) * 1999-11-01 2001-05-10 Mucovax B.V. Production of mammary secretion antibodies in farm animals
WO2002045741A3 (en) * 2000-12-07 2003-05-01 Chiron Spa Helicobacter pylori prime and boost vaccination comprising caga and nap antigens
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
US6974573B2 (en) 1999-11-01 2005-12-13 Mucovax Holdings, B.V. Antibody production in farm animals
US7074454B1 (en) 1999-11-01 2006-07-11 Mucovax Holding B.V. Production of mammary secretion antibodies in farm animals
EP2161035A4 (en) * 2007-05-28 2012-12-26 Kitasato Daiichi Sankyo Vaccine Co Ltd WHOLE-CELLULOSE VEGETABLE COMPOSITION WITH BORDETELLA PARAPERTUSSIS
US8481692B2 (en) 2011-04-22 2013-07-09 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
US9226956B2 (en) 1997-10-20 2016-01-05 Sanofi Pasteur Biologics, Llc Immunization against Clostridium difficile disease
US9320790B2 (en) 2007-09-14 2016-04-26 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing Clostridium difficile toxoids A and B
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
US10787652B2 (en) 2012-10-21 2020-09-29 Pfizer Inc. Compositions and methods relating to a mutant clostridium difficile toxin

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2373332A1 (en) * 2008-12-03 2011-10-12 Boehringer Ingelheim Vetmedica GmbH Process for production of vaccines
WO2011068953A2 (en) * 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944942A (en) * 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
US5182109A (en) * 1988-04-08 1993-01-26 National Institute Of Health Vaccine preparation comprising a bacterial toxin adjuvant
WO1994013264A1 (en) * 1992-12-04 1994-06-23 Ophidian Pharmaceuticals, Inc. Clostridial toxin disease therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141970A (en) * 1975-05-07 1979-02-27 Internationale Octrooimaatschappij "Octropa" B.V. Method for enhancing the resistance of new born mammalian young to gastro-intestinal infections
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
AU4773293A (en) * 1992-07-16 1994-02-14 Oxford University Multiple particulate antigen delivery system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944942A (en) * 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
US5182109A (en) * 1988-04-08 1993-01-26 National Institute Of Health Vaccine preparation comprising a bacterial toxin adjuvant
US5182109C1 (en) * 1988-04-08 2001-10-02 Nat Inst Health Vaccine preparation comprising a bacterial toxin adjuvant
WO1994013264A1 (en) * 1992-12-04 1994-06-23 Ophidian Pharmaceuticals, Inc. Clostridial toxin disease therapy

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AM. J. TROP. MED. HYG., 1994, Vol. 50, No. 5, Suppl., HOLMGREN et al., "Strategies for the Induction of Immune Responses at Mucosal Surfaces Making Use of Cholera Toxin B Subunit as Immunogen, Carrier and Adjuvant", pages 42-54. *
GASTROENTEROLOGY, 1994, Vol. 107, MICHETTI et al., "Immunization of BALB/c Mice Against Helicobacter Felis Infection with Helicobacter Pylori Urease", pages 1002-1011. *
INFECTION AND IMMUNITY, April 1995, Vol. 63, No. 4, PAPPO et al., "Effect of Oral Immunization with Recombinant Urease on Murine Helicobacter Felis Gastritis", pages 1246-1252. *
INFECTION AND IMMUNITY, December 1995, Vol. 63, No. 12, TORRES et al., "Evaluation of Fromalin-Inactivated Clostridium Difficle Vaccines Administered by Parenteral and Mucosal Routes of Immunization in Hamsters", pages 4619-4627. *
MICROBIAL PATHOGENESIS, 1994, Vol. 16, BARROSO et al., "Mutagenesis of the Clostridium Difficile Toxin B Gene and Effect on Cytotoxic Activity", pages 297-303. *
See also references of EP0877623A4 *
THE JOURNAL OF INFECTIOUS DISEASES, 1995, Vol. 172, LEE et al., "Oral Immunization with Recombinant Helicobacter Pylori Urease Induces Secretory IgA Antibodies and Protects Mice from Challenge with Helicobacter Felis", pages 161-172. *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US9226956B2 (en) 1997-10-20 2016-01-05 Sanofi Pasteur Biologics, Llc Immunization against Clostridium difficile disease
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
US7332165B2 (en) 1999-11-01 2008-02-19 Mucovax Holding B.V. Antibody production in farm animals
WO2001032713A1 (en) * 1999-11-01 2001-05-10 Mucovax B.V. Production of mammary secretion antibodies in farm animals
US6974573B2 (en) 1999-11-01 2005-12-13 Mucovax Holdings, B.V. Antibody production in farm animals
US7074454B1 (en) 1999-11-01 2006-07-11 Mucovax Holding B.V. Production of mammary secretion antibodies in farm animals
AU779776B2 (en) * 1999-11-01 2005-02-10 W. Health L.P. Production of mammary secretion antibodies in farm animals
WO2002045741A3 (en) * 2000-12-07 2003-05-01 Chiron Spa Helicobacter pylori prime and boost vaccination comprising caga and nap antigens
EP2161035A4 (en) * 2007-05-28 2012-12-26 Kitasato Daiichi Sankyo Vaccine Co Ltd WHOLE-CELLULOSE VEGETABLE COMPOSITION WITH BORDETELLA PARAPERTUSSIS
US8465754B2 (en) 2007-05-28 2013-06-18 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Bordetella parapertussis whole-cell vaccine composition
US10639362B2 (en) 2007-09-14 2020-05-05 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing Clostridium difficile toxoids A and B
US9687541B2 (en) 2007-09-14 2017-06-27 Sanofi Pastuer Biologies, LLC Pharmaceutical compositions containing Clostridium difficile toxoids A and B
US9320790B2 (en) 2007-09-14 2016-04-26 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing Clostridium difficile toxoids A and B
US8481692B2 (en) 2011-04-22 2013-07-09 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
US10774117B2 (en) 2011-04-22 2020-09-15 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
USRE46376E1 (en) 2011-04-22 2017-04-25 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
US8900597B2 (en) 2011-04-22 2014-12-02 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
USRE46518E1 (en) 2011-04-22 2017-08-22 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
US9745354B2 (en) 2011-04-22 2017-08-29 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
US11535652B2 (en) 2011-04-22 2022-12-27 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
US10597428B2 (en) 2011-04-22 2020-03-24 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
US8557548B2 (en) 2011-04-22 2013-10-15 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
US9187536B1 (en) 2011-04-22 2015-11-17 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
USRE48863E1 (en) 2011-04-22 2021-12-28 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
USRE48862E1 (en) 2011-04-22 2021-12-28 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
US10982198B2 (en) 2012-10-21 2021-04-20 Pfizer Inc. Compositions and methods relating to a mutant Clostridium difficile toxin
US11208633B2 (en) 2012-10-21 2021-12-28 Pfizer Inc. Compositions and methods relating to a mutant Clostridium difficile toxin
US10787652B2 (en) 2012-10-21 2020-09-29 Pfizer Inc. Compositions and methods relating to a mutant clostridium difficile toxin
US11952597B2 (en) 2012-10-21 2024-04-09 Pfizer Inc. Compositions and methods relating to a mutant Clostridium difficile toxin

Also Published As

Publication number Publication date
ZA965737B (en) 1997-05-13
JPH11510793A (ja) 1999-09-21
EP0877623A4 (enrdf_load_stackoverflow) 1998-11-18
AU722653B2 (en) 2000-08-10
CA2226392A1 (en) 1997-01-30
AU6479996A (en) 1997-02-10
EP0877623A1 (en) 1998-11-18
NZ312876A (en) 2000-06-23
CN1195993A (zh) 1998-10-14

Similar Documents

Publication Publication Date Title
Torres et al. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters
Acheson et al. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR
US6019982A (en) Mutant enterotoxin effective as a non-toxic oral adjuvant
Allaoui-Attarki et al. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (DL-lactide-co-glycolide) microspheres
AU722653B2 (en) Intranasal vaccination against gastrointestinal disease
Bahrani et al. Proteus mirabilis flagella and MR/P fimbriae: isolation, purification, N-terminal analysis, and serum antibody response following experimental urinary tract infection
US20080187541A1 (en) Helicobacter pylori adhesin binding group antigen
US5837825A (en) Campylobacter jejuni flagellin/Escherichia coli LT-B fusion protein
US5919463A (en) Clostridium difficle toxins as mucosal adjuvants
Ricci et al. Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii
EP0837692B1 (en) Clostridium difficile toxins and toxoids as mucosal adjuvants
EP1169456A1 (en) Recombinant toxin a/toxin b vaccine against clostridium difficile
US9310381B2 (en) Engineered type IV pilin of Clostridium difficile
US6036953A (en) Heterologous antigens in live cell V. cholerae strains
WO1998023763A9 (en) Heterologous antigens in live cell v. cholerae strains
CA2516661C (en) M. haemolytica outer membrane protein plpe as a vaccine or vaccine component against shipping fever
US7094391B1 (en) Compositions and methods for administering Borrelia burgdorferi antigens
US7049423B2 (en) Use of the RTX secretion system to achieve heterologous polypeptide secretion by Vibrio cholerae
US20020034515A1 (en) Proteus mirabilis-based vaccine
Producing Protective Immunity to Shiga-LikeToxin-I following Oral Immunization with Shiga-Like
Dubois et al. DEVELOPMET OF A MOUSE MODEL OF GASTRIC COLONISATION WTHIHELICOBACTER PYLORI

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96196763.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2226392

Country of ref document: CA

Ref document number: 2226392

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1997 505849

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996924312

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 312876

Country of ref document: NZ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 1996924312

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996924312

Country of ref document: EP